The
Latest

back to news >

Our bench strength is in our extensive experience and team approach. We strive to facilitate each of our client’s needs through strategy, research, and collaboration.

June 20, 2024

Related Posts

Two FDA Approvals to Advance Migraine Care
Two FDA Approvals to Advance Migraine Care
Gallery

Two FDA Approvals to Advance Migraine Care

October 1, 2024
IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders
IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders
Gallery

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

September 17, 2024
FDA Approval: Novel Formulation for Treatment of Schizophrenia
FDA Approval: Novel Formulation for Treatment of Schizophrenia
Gallery

FDA Approval: Novel Formulation for Treatment of Schizophrenia

September 11, 2024
Phase I Studies: On Time with Quality Data
Phase I Studies: On Time with Quality Data
Gallery

Phase I Studies: On Time with Quality Data

July 26, 2024

Tight Timelines: The Biotech Existence

First Patient In 6 Weeks from Written Award

Learn how CRC partnered with an emerging biotech to overcome tight clinical timelines and successfully achieve the First Patient In milestone just 6 weeks from the written award. This case study showcases CRC’s rapid alignment, problem-solving capabilities, and operational excellence that not only met the sponsor’s stringent deadline but also boosted stakeholder confidence.